Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
P/E Ratio
--
P/B Ratio
0.43
Industry P/E
--
Debt to Equity
--
ROE
-0.67 %
ROCE
-68.98 %
Div. Yield
0 %
Book Value
3.22
EPS
-2.16
CFO
$-172.64 Mln
EBITDA
$-130.64 Mln
Net Profit
$-386.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aprea Therapeutics (APRE)
| -51.67 | -29.65 | -62.14 | -69.25 | -62.52 | -70.19 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Aprea Therapeutics (APRE)
| -29.80 | -29.00 | -88.47 | -41.67 | -89.28 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.10 | 10,135.98 | 20.78 | 23.13 | |
| 298.01 | 8,668.61 | 21.55 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 106.95 | 10,030.35 | 30.81 | 14.16 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is APR-1051,... which is in Phase 1 clinical trial for treatment of advanced solid tumors with biomarkers that may predict sensitivity to WEE1 inhibition. Its pipeline includes the ATRN-119, an ATR inhibitor that is in a Phase 1/2a clinical trials for treating advanced solid tumors having at least one mutation in a defined panel of DDR-related genes. It also includes an early-stage program, which is in lead optimization stage for an undisclosed DNA-damage response ("DDR") target. The company is headquartered in Doylestown, Pennsylvania. Address: 3805 Old Easton Road, Doylestown, PA, United States, 18902 Read more
Co-Founder, CEO, President & Director
Dr. Oren Gilad Ph.D.
Co-Founder, CEO, President & Director
Dr. Oren Gilad Ph.D.
Headquarters
Doylestown, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aprea Therapeutics Inc (APRE) stood at $ 24 Mln as on 31-Dec-24
The share price of Aprea Therapeutics Inc (APRE) is $1.59 (NASDAQ) as of 25-Apr-2025 10:54 EDT. Aprea Therapeutics Inc (APRE) has given a return of -62.52% in the last 3 years.
Aprea Therapeutics Inc (APRE) has a market capitalisation of $ 8 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aprea Therapeutics Inc (APRE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aprea Therapeutics Inc (APRE) and enter the required number of quantities and click on buy to purchase the shares of Aprea Therapeutics Inc (APRE).
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is APR-1051, which is in Phase 1 clinical trial for treatment of advanced solid tumors with biomarkers that may predict sensitivity to WEE1 inhibition. Its pipeline includes the ATRN-119, an ATR inhibitor that is in a Phase 1/2a clinical trials for treating advanced solid tumors having at least one mutation in a defined panel of DDR-related genes. It also includes an early-stage program, which is in lead optimization stage for an undisclosed DNA-damage response ("DDR") target. The company is headquartered in Doylestown, Pennsylvania. Address: 3805 Old Easton Road, Doylestown, PA, United States, 18902
The CEO & director of Dr. Oren Gilad Ph.D.. is Aprea Therapeutics Inc (APRE), and CFO & Sr. VP is Dr. Oren Gilad Ph.D..
There is no promoter pledging in Aprea Therapeutics Inc (APRE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Aprea Therapeutics Inc. (APRE) | Ratios |
|---|---|
|
Return on equity(%)
|
-68.98
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aprea Therapeutics Inc (APRE) was $0 Mln.
$-0.03
(
